UCL and the University of Oxford have engineered a CAR T-cell therapy concept aimed at eradicating malignant stem cells driving myeloproliferative neoplasms, using CAR targeting directed to a specific mutation behind rare blood cancers. The preclinical work emphasizes stem-cell selectivity, an area where standard immunotherapy approaches can miss the long-lived disease-initiating compartment. The engineered strategy was described as designed to overcome the durability challenges typical of MPN immunotherapies by focusing on the cellular populations implicated in regeneration and progression. The approach aligns with broader CAR-T development efforts to improve antigen choice and persistence against stem-like disease. For companies working in hematologic malignancies, the publication reinforces demand for mutation- or stem-cell-enriched targeting, particularly in diseases where relapse can be driven by residual initiating cells. The development is best viewed as early, but it adds a new entry point to the next generation of T-cell engager strategies for rare hematologic targets.